Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

- Funding to advance two of Harpoon's immuno-oncology programmes into clinical trials -

LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million.

Arix Bioscience co-led the financing round with New Leaf Venture Partners, and additional new investor Taiho Ventures. They join founding investor MPM Capital, which also participated. Arix Bioscience's Mark Chin will join Harpoon's Board of Directors.

Harpoon created its novel, proprietary trispecific antibody platform (TriTAC(TM)) to harness T cells to kill tumour and other cell types by recruiting T cells and other immune cells. Proceeds from the financing will be used to advance Harpoon's immuno-oncology antibody platform programmes, including moving two lead programmes into clinical trials and expanding the product pipeline through discovery and partnering initiatives. In addition, the company is increasing its commitment to developing research platforms including those that become activated by proteases present in the tumour microenvironment.

Harpoon's first clinical candidate, HPN424, is a prostate-specific membrane antigen (PSMA)-targeting TriTAC(TM). HPN424 is in development for the treatment of metastatic prostate cancer and is expected to enter Phase 1 clinical trials in 2018. Harpoon's second clinical candidate has not been publicly disclosed and will move into the clinic within the next year. The company anticipates additional clinical candidates to be identified and progressed.

Harpoon was founded in 2015 by a team led by Patrick Baeuerle, PhD, Chief Scientific Officer during the development of bispecific T cell engagers (BiTE) at Micromet, which was acquired by Amgen for $1.2bn in 2012. His pioneering work led to the approval of Amgen's Blincyto® (blinatumomab) in 2014 for patients with refractory acute lymphoblastic leukaemia. Harpoon is based in Brisbane, California.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "Harpoon's novel T cell engaging platform has great potential in the discovery and development of important new oncology therapeutics. We are very pleased to be joining the company at this exciting stage alongside the impressive founding team and highly experienced co-investors. This is another important deal for Arix, adding to our rapidly growing collection of world-class Group Businesses."

For more information, please contact:

Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052

Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700

About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit

About Harpoon Therapeutics
Harpoon is a preclinical stage biotechnology company founded by Patrick Baeuerle, Ph.D. and MPM Capital to develop multiple T-cell recruiting platforms leading to therapies for cancer patients and other immunologic disorders. Harpoon created its proprietary TriTAC(TM) biologics platform to harness T cells to kill tumor and other cell types by recruiting T cells and other immune cells. This approach has been optimized to penetrate tissues and extend serum exposure and has the potential to address a broad range of cancers and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC(TM) biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial next year. For more information, please visit